表紙
市場調査レポート

Meiji Seika Pharma Co., Ltd.の製品パイプライン分析

Meiji Seika Pharma Co., Ltd. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321331
出版日 ページ情報 英文 51 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Meiji Seika Pharma Co., Ltd.の製品パイプライン分析 Meiji Seika Pharma Co., Ltd. - Product Pipeline Review - 2015
出版日: 2015年12月23日 ページ情報: 英文 51 Pages
概要

Meiji Seika ファルマは日本に本社をおくファーマシューティカル企業であり、抗菌剤などの製品を中心に医療用医薬品の創薬、開発、製造、販売を行うほか、農業化学製品、動物用医薬品等を製造販売しています。

当レポートでは、Meiji Seika ファルマ における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Meiji Seika ファルマ の基本情報

  • Meiji Seika ファルマ の概要
  • 主要情報
  • 企業情報

Meiji Seika ファルマ :R&Dの概要

  • 主な治療範囲

Meiji Seika ファルマ :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Meiji Seika ファルマ :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 申請登録前の製品/併用療法モダリティ
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Meiji Seika ファルマ :薬剤プロファイル

  • talaporfin sodium
  • asenapine maleate
  • fluvoxamine maleate
  • ME-1111
  • mirtazapine
  • udenafil
  • ziprasidone hydrochloride
  • arbekacin
  • OP-0595
  • safinamide
  • trastuzumab biosimilar
  • CP-9531

Meiji Seika ファルマ :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Meiji Seika ファルマ :最新のパイプライン情報

Meiji Seika ファルマ :開発が休止された製品

Meiji Seika ファルマ :開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品
    • AM-831
    • ME-3738

Meiji Seika ファルマ :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07904CDB

Summary

Global Markets Direct's, 'Meiji Seika Pharma Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Meiji Seika Pharma Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Meiji Seika Pharma Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Meiji Seika Pharma Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Meiji Seika Pharma Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Meiji Seika Pharma Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Meiji Seika Pharma Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Meiji Seika Pharma Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Meiji Seika Pharma Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Meiji Seika Pharma Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Meiji Seika Pharma Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Meiji Seika Pharma Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Meiji Seika Pharma Co., Ltd. Snapshot
    • Meiji Seika Pharma Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Meiji Seika Pharma Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Meiji Seika Pharma Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Meiji Seika Pharma Co., Ltd. - Pipeline Products Glance
    • Meiji Seika Pharma Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Meiji Seika Pharma Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Meiji Seika Pharma Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Meiji Seika Pharma Co., Ltd. - Drug Profiles
    • asenapine maleate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fluvoxamine maleate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ziprasidone mesylate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • safinamide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ME-1111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mirtazapine ODT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • talaporfin sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • udenafil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • arbekacin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trastuzumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CP-9531
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Meiji Seika Pharma Co., Ltd. - Pipeline Analysis
    • Meiji Seika Pharma Co., Ltd. - Pipeline Products by Target
    • Meiji Seika Pharma Co., Ltd. - Pipeline Products by Route of Administration
    • Meiji Seika Pharma Co., Ltd. - Pipeline Products by Molecule Type
    • Meiji Seika Pharma Co., Ltd. - Pipeline Products by Mechanism of Action
  • Meiji Seika Pharma Co., Ltd. - Recent Pipeline Updates
  • Meiji Seika Pharma Co., Ltd. - Dormant Projects
  • Meiji Seika Pharma Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • AM-831
      • ME-3738
  • Meiji Seika Pharma Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Meiji Seika Pharma Co., Ltd., Key Information
  • Meiji Seika Pharma Co., Ltd., Key Facts
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Indication, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Stage of Development, 2015
  • Meiji Seika Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Meiji Seika Pharma Co., Ltd. - Partnered Products in Pipeline, 2015
  • Meiji Seika Pharma Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Meiji Seika Pharma Co., Ltd. - Out-Licensed Products in Pipeline, 2015
  • Meiji Seika Pharma Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Meiji Seika Pharma Co., Ltd. - Pre-Registration, 2015
  • Meiji Seika Pharma Co., Ltd. - Phase III, 2015
  • Meiji Seika Pharma Co., Ltd. - Phase II, 2015
  • Meiji Seika Pharma Co., Ltd. - Phase I, 2015
  • Meiji Seika Pharma Co., Ltd. - Preclinical, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Target, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Route of Administration, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Molecule Type, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Meiji Seika Pharma Co., Ltd. - Recent Pipeline Updates, 2015
  • Meiji Seika Pharma Co., Ltd. - Dormant Developmental Projects,2015
  • Meiji Seika Pharma Co., Ltd. - Discontinued Pipeline Products, 2015
  • Meiji Seika Pharma Co., Ltd., Subsidiaries

List of Figures

  • Meiji Seika Pharma Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Stage of Development, 2015
  • Meiji Seika Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Meiji Seika Pharma Co., Ltd. - Partnered Products in Pipeline, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top